

Susan Davis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3810539/publications.pdf>

Version: 2024-02-01

407
papers

23,974
citations

7551

77
h-index

9839

141
g-index

432
all docs

432
docs citations

432
times ranked

16108
citing authors

#	ARTICLE	IF	CITATIONS
1	Approach to the Patient With New-Onset Secondary Amenorrhea: Is This Primary Ovarian Insufficiency?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 825-835.	1.8	5
2	Functional hypothalamic amenorrhoea: a diagnosis of exclusion. <i>Medical Journal of Australia</i> , 2022, 216, 73-76.	0.8	2
3	Reply: A single cut-off value of anti-Mullerian hormone should not be used for the diagnosis of PCOS in all reproductive-aged women. <i>Human Reproduction</i> , 2022, , .	0.4	0
4	Associations between blood sex steroid concentrations and risk of major adverse cardiovascular events in healthy older women in Australia: a prospective cohort substudy of the ASPREE trial. <i>The Lancet Healthy Longevity</i> , 2022, 3, e109-e118.	2.0	15
5	Treating menopause " MHT and beyond. <i>Nature Reviews Endocrinology</i> , 2022, 18, 490-502.	4.3	37
6	Testosterone use in postmenopausal women. <i>Climacteric</i> , 2021, 24, 46-50.	1.1	5
7	International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. <i>Journal of Sexual Medicine</i> , 2021, 18, 849-867.	0.3	40
8	Longitudinal changes over three years in sex steroid hormone levels in women aged 70 years and over. <i>Clinical Endocrinology</i> , 2021, 94, 443-448.	1.2	10
9	Letter to the Editor: "Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1917-e1918.	1.8	0
10	Androgens in premenopausal women and women with premature ovarian insufficiency. <i>Climacteric</i> , 2021, 24, 459-465.	1.1	3
11	A prospective controlled study of sexual function and sexually related personal distress up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy. <i>Menopause</i> , 2021, 28, 748-755.	0.8	6
12	Use of Testosterone in Postmenopausal Women. <i>Endocrinology and Metabolism Clinics of North America</i> , 2021, 50, 113-124.	1.2	1
13	Differing performance of two assays for the measurement of anti-Mullerian hormone in premenopausal women: A cross-sectional study. <i>Clinical Endocrinology</i> , 2021, 95, 169-175.	1.2	7
14	A core outcome set for vasomotor symptoms associated with menopause: the COMMA (Core Outcomes) Tj ETQq0,0,0 rgBT /Overlock 1	0.8	21
15	International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. <i>Climacteric</i> , 2021, 24, 533-550.	1.1	4
16	International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. <i>Journal of Women's Health</i> , 2021, 30, 474-491.	1.5	22
17	Use of community-based reference ranges to estimate the prevalence of polycystic ovary syndrome by the recognised diagnostic criteria, a cross-sectional study. <i>Human Reproduction</i> , 2021, 36, 1611-1620.	0.4	10
18	A core outcome set for genitourinary symptoms associated with menopause: the COMMA (Core) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6	0.8	19

#	ARTICLE	IF	CITATIONS
19	Health-care providers' views of menopause and its management: a qualitative study. <i>Climacteric</i> , 2021, 24, 612-617.	1.1	10
20	Testosterone and androstenedione are positively associated with anti-Müllerian hormone in premenopausal women. <i>Clinical Endocrinology</i> , 2021, 95, 752-759.	1.2	1
21	Substituting serum anti-Müllerian hormone for polycystic ovary morphology increases the number of women diagnosed with polycystic ovary syndrome: a community-based cross-sectional study. <i>Human Reproduction</i> , 2021, 37, 109-118.	0.4	11
22	Menopause workplace policy: The way forward or backward?. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2021, 61, 986-989.	0.4	2
23	Iron insufficiency among young Australian women: a population-based survey. <i>Internal Medicine Journal</i> , 2020, 50, 420-426.	0.5	0
24	Prevalence of and Risk Factors for Depressive Symptoms and Antidepressant Use in Young Australian Women: A Cross-Sectional Study. <i>Journal of Women's Health</i> , 2020, 30, 997-1005.	1.5	1
25	Workshop on normal reference ranges for estradiol in postmenopausal women, September 2019, Chicago, Illinois. <i>Menopause</i> , 2020, 27, 614-624.	0.8	12
26	Reflecting back and looking forward. <i>Climacteric</i> , 2020, 23, 530-531.	1.1	0
27	Associations between androgens and sexual function in premenopausal women: a cross-sectional study. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 693-702.	5.5	30
28	Australian women's understanding of menopause and its consequences: a qualitative study. <i>Climacteric</i> , 2020, 23, 622-628.	1.1	15
29	Prevalence of Low Sexual Desire with Associated Distress Across the Adult Life Span: An Australian Cross-Sectional Study. <i>Journal of Sexual Medicine</i> , 2020, 17, 1885-1895.	0.3	10
30	Approach to Managing a Postmenopausal Patient. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3792-3806.	1.8	3
31	Response to Letter to the Editor: "Distribution of Body Hair in Young Australian Women and Associations with Serum Androgen Concentrations". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3049-e3050.	1.8	0
32	Ultrasensitive Serum Estradiol Measurement by Liquid Chromatography-Mass Spectrometry in Postmenopausal Women and Mice. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa086.	0.1	19
33	Response to Letter to the Editor: "Global Consensus Position Statement on the Use of Testosterone Therapy for Women". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2313-e2314.	1.8	2
34	Estrone Is a Strong Predictor of Circulating Estradiol in Women Age 70 Years and Older. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3348-e3354.	1.8	14
35	Androgen Therapy for Postmenopausal Women. , 2020, , 187-193.		0
36	Distribution of Body Hair in Young Australian Women and Associations With Serum Androgen Concentrations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1186-1195.	1.8	10

#	ARTICLE	IF	CITATIONS
37	The prevalence of sexual dysfunctions and sexually related distress in young women: a cross-sectional survey. <i>Fertility and Sterility</i> , 2020, 113, 426-434.	0.5	22
38	Underlying Breast Cancer Risk and Menopausal Hormone Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2299-e2307.	1.8	20
39	Analysis of variants in <i>GATA4</i> and <i>FOG2</i> / <i>ZFPM2</i> demonstrates benign contribution to 46,XY disorders of sex development. <i>Molecular Genetics & Genomic Medicine</i> , 2020, 8, e1095.	0.6	16
40	Methodological Challenges in Studying Testosterone Therapies for Hypoactive Sexual Desire Disorder in Women. <i>Journal of Sexual Medicine</i> , 2020, 17, 585-594.	0.3	5
41	The prevalence of hypoactive sexual desire disorder in Australian and Iranian women at midlife. <i>Menopause</i> , 2020, 27, 1274-1280.	0.8	3
42	Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 754-766.	5.5	140
43	Hormonal contraceptive use in Australian women: Who is using what?. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2019, 59, 717-724.	0.4	13
44	Androgens During the Reproductive Years: What Is Normal for Women?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5382-5392.	1.8	76
45	Menopausal hormone therapy: is there cause for concern?. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 825-827.	5.5	2
46	Effects of testosterone therapy for women: a systematic review and meta-analysis protocol. <i>Systematic Reviews</i> , 2019, 8, 19.	2.5	15
47	What is the position of testosterone in the care of women?. <i>Climacteric</i> , 2019, 22, 427-428.	1.1	0
48	Global Consensus Position Statement on the Use of Testosterone Therapy for Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4660-4666.	1.8	147
49	Global Consensus Position Statement on the use of Testosterone Therapy for Women. <i>Maturitas</i> , 2019, 128, 89-93.	1.0	12
50	Global Consensus Position Statement on the Use of Testosterone Therapy for Women. <i>Journal of Sexual Medicine</i> , 2019, 16, 1331-1337.	0.3	22
51	Global Consensus Position Statement on the Use of Testosterone Therapy for Women. <i>Climacteric</i> , 2019, 22, 429-434.	1.1	50
52	The Kupperman Index undressed. <i>Maturitas</i> , 2019, 126, 90-91.	1.0	10
53	Challenges in recruitment to an epidemiological study of young Australian women: the Grollo & Ruzzene Foundation Young Women's Health Study. <i>Australian and New Zealand Journal of Public Health</i> , 2019, 43, 131-136.	0.8	16
54	Exogenous Testosterone Does Not Influence 11-Oxygenated C19 Steroid Concentrations in Healthy Postmenopausal Women. <i>Journal of the Endocrine Society</i> , 2019, 3, 670-677.	0.1	10

#	ARTICLE	IF	CITATIONS
55	Testosterone and Estrone Increase From the Age of 70 Years: Findings From the Sex Hormones in Older Women Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 6291-6300.	1.8	37
56	Depressive symptoms and associated factors among Iranian women at midlife: a community-based, cross-sectional study. <i>Menopause</i> , 2019, 26, 1125-1132.	0.8	4
57	SAT-LB001 Traditional Sex Steroids and Ketoandrogen Levels by Menstrual Cycle Stage, Age and Body Mass Index in Women Aged 18-39 Years. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.1	0
58	A systematic review of intravaginal testosterone for the treatment of vulvovaginal atrophy. <i>Menopause</i> , 2018, 25, 704-709.	0.8	33
59	Prevalence of sexual symptoms in relation to menopause in women in Asia: a systematic review. <i>Menopause</i> , 2018, 25, 231-238.	0.8	12
60	The International Society for the Study of Women's Sexual Health Process of Care for Management of Hypoactive Sexual Desire Disorder in Women. <i>Mayo Clinic Proceedings</i> , 2018, 93, 467-487.	1.4	166
61	Testosterone for Poor Ovarian Responders: Lessons From Ovarian Physiology. <i>Reproductive Sciences</i> , 2018, 25, 980-982.	1.1	25
62	Depressive symptoms and their risk factors in midlife women in the Middle East: a systematic review. <i>Climacteric</i> , 2018, 21, 13-21.	1.1	11
63	Menopause, lung function and obstructive lung disease outcomes: a systematic review. <i>Climacteric</i> , 2018, 21, 3-12.	1.1	19
64	Identification of the Gender-Specific Health Needs of Women Following Lung Transplantation. <i>Journal of Women's Health</i> , 2018, 27, 485-491.	1.5	1
65	Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 years. <i>Menopause</i> , 2018, 25, 1331-1338.	0.8	14
66	Awareness and use of iodine supplementation among Australian women attending a low-risk pregnancy clinic. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2018, 58, E16-E17.	0.4	1
67	Intravaginal Testosterone Improves Sexual Satisfaction and Vaginal Symptoms Associated With Aromatase Inhibitors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 4146-4154.	1.8	42
68	Bothersome menopausal symptoms amongst postmenopausal Iranian women. <i>Climacteric</i> , 2018, 21, 586-593.	1.1	11
69	Understanding variation in prevalence estimates of polycystic ovary syndrome: a systematic review and meta-analysis. <i>Human Reproduction Update</i> , 2018, 24, 694-709.	5.2	134
70	Sexual well-being after menopause: An International Menopause Society White Paper. <i>Climacteric</i> , 2018, 21, 415-427.	1.1	89
71	Menopause â€œ a new beginning. <i>Climacteric</i> , 2018, 21, 306-307.	1.1	1
72	Androgens in postmenopausal women. <i>Gynakologische Endokrinologie</i> , 2018, 16, 123-127.	0.1	0

#	ARTICLE	IF	CITATIONS
73	Routine Screening for Urinary Incontinence in Women: Caution Advised. <i>Annals of Internal Medicine</i> , 2018, 169, 345-346.	2.0	2
74	The benefits of adding metformin to tamoxifen to protect the endometrium—A randomized placebo-controlled trial. <i>Clinical Endocrinology</i> , 2018, 89, 605-612.	1.2	20
75	Types of urinary incontinence in Bangladeshi women at midlife: Prevalence and risk factors. <i>Maturitas</i> , 2018, 116, 18-23.	1.0	13
76	Poor general health and lower levels of vitality are associated with persistent, high-intensity low back pain and disability in community-based women: A prospective cohort study. <i>Maturitas</i> , 2018, 113, 7-12.	1.0	10
77	Negative beliefs about back pain are associated with persistent, high levels of low back disability in community-based women. <i>Menopause</i> , 2018, 25, 977-984.	0.8	19
78	The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review. <i>Menopause</i> , 2018, 25, 837-847.	0.8	105
79	Moderate—Severe Vasomotor Symptoms Are Associated with Moderate—Severe Depressive Symptoms. <i>Journal of Women's Health</i> , 2017, 26, 712-718.	1.5	46
80	Hypoactive sexual desire dysfunction in community-dwelling older women. <i>Menopause</i> , 2017, 24, 391-399.	0.8	32
81	Prevalence and Predictors of Low Sexual Desire, Sexually Related Personal Distress, and Hypoactive Sexual Desire Dysfunction in a Community-Based Sample of Midlife Women. <i>Journal of Sexual Medicine</i> , 2017, 14, 675-686.	0.3	72
82	Androgens in postmenopausal women: a review. <i>Menopause</i> , 2017, 24, 970-979.	0.8	33
83	Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3647-3661.	1.8	89
84	Aromatase Inhibitors Are Associated with Low Sexual Desire Causing Distress and Fecal Incontinence in Women: An Observational Study. <i>Journal of Sexual Medicine</i> , 2017, 14, 1566-1574.	0.3	23
85	Vasomotor symptoms are associated with depressive symptoms in community-dwelling older women. <i>Menopause</i> , 2017, 24, 1365-1371.	0.8	3
86	Vasomotor symptoms in women in Asia appear comparable with women in Western countries: a systematic review. <i>Menopause</i> , 2017, 24, 1313-1322.	0.8	24
87	Is Estrogen the Antidote for Menopausal Depression?. <i>Journal of Women's Health</i> , 2017, 26, 1-2.	1.5	1
88	Low use of effective and safe therapies for moderate to severe menopausal symptoms. <i>Menopause</i> , 2016, 23, 11-17.	0.8	30
89	The use of micronised progesterone for menopausal hormone therapy, a clinical practice audit. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2016, 56, 323-325.	0.4	0
90	Authors'™ response to Letter to the Editor on awareness of breast cancer and barriers to breast screening uptake in Bangladesh: A population-based survey. <i>Maturitas</i> , 2016, 88, 58.	1.0	1

#	ARTICLE	IF	CITATIONS
91	Symptomatic pelvic floor disorders in community-dwelling older Australian women. <i>Maturitas</i> , 2016, 85, 34-41.	1.0	41
92	Clinical audit of estradiol implant therapy: Long duration of action and implications in non-hysterectomised women. <i>Maturitas</i> , 2016, 94, 84-86.	1.0	5
93	Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women. <i>JAMA Psychiatry</i> , 2016, 73, 947.	6.0	74
94	The prevalence of symptomatic pelvic floor disorders in women in Bangladesh. <i>Climacteric</i> , 2016, 19, 558-564.	1.1	28
95	Role of Estrogens and Estrogen-Like Compounds in Female Sexual Function and Dysfunction. <i>Journal of Sexual Medicine</i> , 2016, 13, 305-316.	0.3	75
96	Prevalence and severity of vasomotor symptoms and joint pain in women at midlife in Bangladesh: a population-based survey. <i>Menopause</i> , 2016, 23, 731-739.	0.8	22
97	Menopausal vasomotor symptoms are associated with poor self-assessed work ability. <i>Maturitas</i> , 2016, 87, 33-39.	1.0	49
98	Awareness of breast cancer and barriers to breast screening uptake in Bangladesh: A population based survey. <i>Maturitas</i> , 2016, 84, 68-74.	1.0	34
99	Hormones and Female Sexual Dysfunction: Beyond Estrogens and Androgensâ€”Findings From the Fourth International Consultation on Sexual Medicine. <i>Journal of Sexual Medicine</i> , 2016, 13, 283-290.	0.3	31
100	Androgens and Female Sexual Function and Dysfunctionâ€”Findings From the Fourth International Consultation of Sexual Medicine. <i>Journal of Sexual Medicine</i> , 2016, 13, 168-178.	0.3	85
101	Vasomotor and sexual symptoms in older Australian women: a cross-sectional study. <i>Fertility and Sterility</i> , 2016, 105, 149-155.e1.	0.5	41
102	Authors' reply: Communicating evidence-based practice in menopause. <i>Nature Reviews Disease Primers</i> , 2015, 1, .	18.1	5
103	Lack of Understanding of Cervical Cancer and Screening Is the Leading Barrier to Screening Uptake in Women at Midlife in Bangladesh: Population-Based Cross-Sectional Survey. <i>Oncologist</i> , 2015, 20, 1386-1392.	1.9	22
104	Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 years. <i>Menopause</i> , 2015, 22, 694-701.	0.8	90
105	Use of complementary and alternative medicines for menopausal symptoms in Australian women aged 40â€“65 years. <i>Medical Journal of Australia</i> , 2015, 203, 146-146.	0.8	16
106	Menopausal hormone therapyâ€”ovarian cancer risk revisited. <i>Nature Reviews Endocrinology</i> , 2015, 11, 322-323.	4.3	3
107	Targeted assessment of fracture risk in women at midlife. <i>Osteoporosis International</i> , 2015, 26, 1705-1712.	1.3	7
108	Testosterone in women: can the challenges be met?. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 588-590.	5.5	6

#	ARTICLE	IF	CITATIONS
109	Reply. Arthritis and Rheumatology, 2015, 67, 315-316.	2.9	0
110	Prevalence of menopausal symptoms in Asian midlife women: a systematic review. Climacteric, 2015, 18, 157-176.	1.1	58
111	Vasomotor symptoms and urogenital atrophy in older women: a systematic review. Climacteric, 2015, 18, 112-120.	1.1	22
112	Educating other practitioners on how to assess menopausal women. Maturitas, 2015, 81, 124.	1.0	0
113	Menopause. Nature Reviews Disease Primers, 2015, 1, 15004.	18.1	288
114	Minimal-trauma fracture in women with breast cancer surviving for at least 5 years from diagnosis. Osteoporosis International, 2015, 26, 795-800.	1.3	8
115	Pharmacokinetics of a transdermal testosterone cream in healthy postmenopausal women. Menopause, 2015, 22, 44-49.	0.8	20
116	Factors associated with magnetic resonance imaging defined patellar tendinopathy in community-based middle-aged women: a prospective cohort study. BMC Musculoskeletal Disorders, 2015, 16, 184.	0.8	18
117	Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3975-4011.	1.8	589
118	Testosterone in women—the clinical significance. Lancet Diabetes and Endocrinology, 2015, 3, 980-992.	5.5	181
119	Moderate-severely bothersome vasomotor symptoms are associated with lowered psychological general wellbeing in women at midlife. Maturitas, 2015, 81, 487-492.	1.0	49
120	Bangladesh Midlife Women's Health Study (BMWHS): Methods, challenges and experiences. Maturitas, 2015, 80, 89-94.	1.0	10
121	Metformin for overweight women at midlife: a double-blind, randomized, controlled trial. Climacteric, 2015, 18, 270-277.	1.1	16
122	Letter to the Editor: Randolph J, et al. Masturbation Frequency and Sexual Function Domains Are Associated With Serum Reproductive Hormone Levels Across the Menopausal Transition. Journal of Clinical Endocrinology and Metabolism, 2015, 100, L25-L25.	1.8	0
123	Intended follow up of women with breast cancer at low risk of recurrence and at least 5 years from diagnosis. Internal Medicine Journal, 2014, 44, 332-338.	0.5	4
124	Incidence of Total Knee and Hip Replacement for Osteoarthritis in Relation to Circulating Sex Steroid Hormone Concentrations in Women. Arthritis and Rheumatology, 2014, 66, 2144-2151.	2.9	35
125	Transdermal testosterone improves verbal learning and memory in postmenopausal women not on oestrogen therapy. Clinical Endocrinology, 2014, 81, 621-628.	1.2	26
126	Women's expectations and experiences of hormone treatment for sexual dysfunction. Climacteric, 2014, 17, 674-681.	1.1	8

#	ARTICLE	IF	CITATIONS
127	The North American Menopause Society Recommendations for Clinical Care of Midlife Women. <i>Menopause</i> , 2014, 21, 1038-1062.	0.8	258
128	Menopausal symptoms in breast cancer survivors nearly 6 years after diagnosis. <i>Menopause</i> , 2014, 21, 1075-1081.	0.8	48
129	A comparison of the characteristics, treatment and outcome after 5years, of Australian women aged 70+with those aged<70years at the time of diagnosis of breast cancer. <i>Journal of Geriatric Oncology</i> , 2014, 5, 141-147.	0.5	5
130	Persistent breast pain 5Âyears after treatment of invasive breast cancer is largely unexplained by factors associated with treatment. <i>Journal of Cancer Survivorship</i> , 2014, 8, 1-8.	1.5	30
131	Hormone therapy to treat menopause“breaking a taboo. <i>Nature Reviews Endocrinology</i> , 2014, 10, 6-8.	4.3	4
132	Testosterone Improves Antidepressant-Emergent Loss of Libido in Women: Findings from a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Sexual Medicine</i> , 2014, 11, 831-839.	0.3	36
133	Application Site Affects the Pharmacokinetics of Topical Testosterone Applied to the Axilla Compared With the Inner Arm. <i>Clinical Therapeutics</i> , 2014, 36, 1395-1401.	1.1	0
134	Effects of testosterone on visuospatial function and verbal fluency in postmenopausal women. <i>Menopause</i> , 2014, 21, 410-414.	0.8	22
135	Prevalence of menopausal symptoms in Australian women at midlife: a systematic review. <i>Climacteric</i> , 2014, 17, 529-539.	1.1	24
136	Prevention of diseases after menopause. <i>Climacteric</i> , 2014, 17, 540-556.	1.1	197
137	Obesity is associated with a poorer prognosis in women with hormone receptor positive breast cancer. <i>Maturitas</i> , 2014, 79, 279-286.	1.0	36
138	A Practitioner's Toolkit for Managing the Menopause. <i>Climacteric</i> , 2014, 17, 564-579.	1.1	64
139	Association between urinary C-telopeptide fragments of type II collagen and knee structure in middle-aged women without clinical knee disease. <i>Osteoarthritis and Cartilage</i> , 2014, 22, 1136-1141.	0.6	7
140	Androgen Therapy in Women: A Reappraisal: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3489-3510.	1.8	261
141	A four week randomised control trial of adjunctive medroxyprogesterone and tamoxifen in women with mania. <i>Psychoneuroendocrinology</i> , 2014, 43, 52-61.	1.3	26
142	The association between vasomotor symptoms and depression during perimenopause: A systematic review. <i>Maturitas</i> , 2014, 77, 111-117.	1.0	75
143	Androgen treatment of postmenopausal women. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014, 142, 107-114.	1.2	31
144	The prevalence of vitamin D deficiency and relationship with fracture risk in older women presenting in Australian general practice. <i>Australasian Journal on Ageing</i> , 2013, 32, 177-183.	0.4	9

#	ARTICLE	IF	CITATIONS
145	Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. <i>Climacteric</i> , 2013, 16, 316-337.	1.1	255
146	Use of imaging in surveillance of women with early stage breast cancer. <i>ANZ Journal of Surgery</i> , 2013, 83, 129-134.	0.3	3
147	Lymphedema: experience of a cohort of women with breast cancer followed for 4 years after diagnosis in Victoria, Australia. <i>Supportive Care in Cancer</i> , 2013, 21, 2017-2024.	1.0	15
148	Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. <i>Lancet</i> , 2013, 381, 805-816.	6.3	1,664
149	Pregnancy-associated breast cancer and pregnancy following treatment for breast cancer, in a cohort of women from Victoria, Australia, with a first diagnosis of invasive breast cancer. <i>Breast</i> , 2013, 22, 980-985.	0.9	8
150	Comparison of plain vertebral X-ray and dual-energy X-ray absorptiometry for the identification of older women for fracture prevention in primary care. <i>Internal Medicine Journal</i> , 2013, 43, 38-45.	0.5	1
151	Change to Either a Nonandrogenic or Androgenic Progestin-Containing Oral Contraceptive Preparation is Associated with Improved Sexual Function in Women with Oral Contraceptive-Associated Sexual Dysfunction. <i>Journal of Sexual Medicine</i> , 2013, 10, 3069-3079.	0.3	53
152	Evaluation of a Bladder Cancer Cluster in a Population of Criminal Investigators with the Bureau of Alcohol, Tobacco, Firearms and Explosives – Part 2: The Association of Cancer Risk and Fire Scene Investigation. <i>Journal of Environmental and Public Health</i> , 2013, 2013, 1-10.	0.4	0
153	Continuous-combined oral estradiol/drospirenone has no detrimental effect on cognitive performance and improves estrogen deficiency symptoms in early postmenopausal women. <i>Menopause</i> , 2013, 20, 1020-1026.	0.8	17
154	Androgen therapy in women, beyond libido. <i>Climacteric</i> , 2013, 16, 18-24.	1.1	27
155	Modes of Infant Feeding and the Occurrence of Coughing/Wheezing in the First Year of Life. <i>Journal of Human Lactation</i> , 2013, 29, 71-80.	0.8	42
156	Aromatase inhibitors associated with knee subchondral bone expansion without cartilage loss. <i>Climacteric</i> , 2013, 16, 632-638.	1.1	3
157	Urinary Incontinence in Young Nulligravid Women. <i>Annals of Internal Medicine</i> , 2013, 158, 139.	2.0	0
158	Endogenous estrogen and androgen levels are not independent predictors of lipid levels in postmenopausal women. <i>Menopause</i> , 2013, 20, 640-645.	0.8	18
159	Androgen use for low sexual desire in midlife women. <i>Menopause</i> , 2013, 20, 795-797.	0.8	5
160	Patterns of use of oral adjuvant endocrine therapy in Australian breast cancer survivors 5 years from diagnosis. <i>Menopause</i> , 2013, 20, 721-726.	0.8	8
161	Understanding discontinuation of oral adjuvant endocrine therapy by women with hormone receptor-positive invasive breast cancer nearly 4 years from diagnosis. <i>Menopause</i> , 2013, 20, 15-21.	0.8	20
162	Climacteric Commentaries. <i>Climacteric</i> , 2012, 15, 398-406.	1.1	0

#	ARTICLE	IF	CITATIONS
163	Cosmetic surgery prior to diagnosis of breast cancer. <i>Climacteric</i> , 2012, 15, 195-199.	1.1	0
164	Evaluation of a Bladder Cancer Cluster in a Population of Criminal Investigators with the Bureau of Alcohol, Tobacco, Firearms and Explosivesâ€™ Part 1: The Cancer Incidence. <i>Journal of Environmental and Public Health</i> , 2012, 2012, 1-10.	0.4	1
165	Management strategies in SSRI-associated sexual dysfunction in women at midlife. <i>Climacteric</i> , 2012, 15, 306-316.	1.1	19
166	Urinary Incontinence in Young Nulligravid Women. <i>Annals of Internal Medicine</i> , 2012, 157, 87.	2.0	40
167	Sexual Function, Incontinence, and Wellbeing in Women after Rectal Cancerâ€™ A Review of the Evidence. <i>Journal of Sexual Medicine</i> , 2012, 9, 2749-2758.	0.3	46
168	The contribution of SHBG to the variation in HOMAâ€™R is not dependent on endogenous oestrogen or androgen levels in postmenopausal women. <i>Clinical Endocrinology</i> , 2012, 77, 541-547.	1.2	28
169	Fatty Acids in Breast Milk Associated with Asthma-Like Symptoms and Atopy in Infancy: A Longitudinal Study. <i>Journal of Asthma</i> , 2012, 49, 926-934.	0.9	22
170	The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI. <i>Climacteric</i> , 2012, 15, 267-274.	1.1	89
171	A research participant's rights as an ethical dilemma. <i>Australian and New Zealand Journal of Public Health</i> , 2012, 36, 508-510.	0.8	2
172	Hormonal therapies for new onset and relapsed depression during perimenopause. <i>Maturitas</i> , 2012, 73, 127-133.	1.0	37
173	An update on the pharmacological management of female sexual dysfunction. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2131-2142.	0.9	23
174	Understanding weight gain at menopause. <i>Climacteric</i> , 2012, 15, 419-429.	1.1	430
175	Can the severity of menopausal symptoms be predicted?. <i>BMJ: British Medical Journal</i> , 2012, 344, d7664-d7664.	2.4	0
176	Breast cancer survivors' beliefs about the causes of breast cancer. <i>Psycho-Oncology</i> , 2012, 21, 724-729.	1.0	29
177	Changes in patterns of use of cigarettes and alcohol in women after a first diagnosis of invasive breast cancer: a cohort study of women from Victoria, Australia. <i>Supportive Care in Cancer</i> , 2012, 20, 783-789.	1.0	14
178	Breast reconstruction following mastectomy for invasive breast cancer is strongly influenced by demographic factors in women in Victoria, Australia. <i>Breast</i> , 2012, 21, 394-400.	0.9	23
179	Efficacy and Safety of Testosterone in the Management of Hypoactive Sexual Desire Disorder in Postmenopausal Women. <i>Journal of Sexual Medicine</i> , 2012, 9, 1134-1148.	0.3	91
180	Climacteric commentaries. Sexual activity and satisfaction in community-dwelling older women. <i>Climacteric</i> , 2012, 15, 399-400.	1.1	0

#	ARTICLE	IF	CITATIONS
181	Incidence and Resolution Rates of Different Types of Urinary Incontinence in Women: Findings From a Cohort Study. <i>Journal of Urology</i> , 2011, 185, 1331-1337.	0.2	27
182	Vaginal DHEA to treat menopause related atrophy: A review of the evidence. <i>Maturitas</i> , 2011, 70, 22-25.	1.0	56
183	Testosterone improves verbal learning and memory in postmenopausal women: Results from a pilot study. <i>Maturitas</i> , 2011, 70, 307-311.	1.0	42
184	Androgenic hormones and aging – The link with female sexual function. <i>Hormones and Behavior</i> , 2011, 59, 745-753.	1.0	37
185	Cardiovascular and cancer safety of testosterone in women. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2011, 18, 198-203.	1.2	39
186	Simplifying screening for osteoporosis in Australian primary care. <i>Menopause</i> , 2011, 18, 53-59.	0.8	13
187	Dehydroepiandrosterone Replacement for Postmenopausal Women. <i>Obstetrical and Gynecological Survey</i> , 2011, 66, 490-491.	0.2	0
188	Prevalence of fecal incontinence and its relationship with urinary incontinence in women living in the community. <i>Menopause</i> , 2011, 18, 685-689.	0.8	43
189	Sexual Function After Breast Cancer. <i>Journal of Sexual Medicine</i> , 2011, 8, 294-302.	0.3	150
190	DHEA Replacement for Postmenopausal Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1642-1653.	1.8	131
191	Climacteric commentaries. <i>Climacteric</i> , 2011, 14, 598-606.	1.1	0
192	Climacteric Commentaries. <i>Climacteric</i> , 2011, 14, 505-512.	1.1	1
193	Sex and perimenopause. <i>Australian Family Physician</i> , 2011, 40, 274-8.	0.5	8
194	Visceral fat accumulation and cardiovascular disease risk profile. <i>Climacteric</i> , 2011, 14, 599-600.	1.1	0
195	Urinary incontinence is associated with lower psychological general well-being in community-dwelling women. <i>Menopause</i> , 2010, 17, 332-337.	0.8	37
196	Use of complementary and alternative therapy by women in the first 2 years after diagnosis and treatment of invasive breast cancer. <i>Menopause</i> , 2010, 17, 1004-1009.	0.8	14
197	Psychological well-being in a cohort of women with invasive breast cancer nearly 2 years after diagnosis. <i>Supportive Care in Cancer</i> , 2010, 18, 921-929.	1.0	17
198	The Relationship Between Hormone Therapy Use at the Time of Diagnosis of Breast Cancer and Tumor Characteristics. <i>Hormones and Cancer</i> , 2010, 1, 93-99.	4.9	1

#	ARTICLE	IF	CITATIONS
199	Greater superior than inferior parietal lobule activation with increasing rotation angle during mental rotation: An fMRI study. <i>Neuropsychologia</i> , 2010, 48, 529-535.	0.7	93
200	Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. <i>Psychoneuroendocrinology</i> , 2010, 35, 1142-1147.	1.3	106
201	Endocrine Aspects of Women's Sexual Function. <i>Journal of Sexual Medicine</i> , 2010, 7, 561-585.	0.3	85
202	Responses to the Proposed DSM-V Changes. <i>Journal of Sexual Medicine</i> , 2010, 7, 1998-2014.	0.3	23
203	Should women receive androgen replacement therapy, and if so, how?. <i>Clinical Endocrinology</i> , 2010, 72, 149-154.	1.2	8
204	Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. <i>Climacteric</i> , 2010, 13, 121-131.	1.1	152
205	Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, s1-s66.	1.8	512
206	Drugs for the treatment of menopausal symptoms. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1329-1341.	0.9	7
207	DHEA for postmenopausal women: A review of the evidence. <i>Maturitas</i> , 2010, 66, 172-179.	1.0	79
208	Validity and cultural equivalence of the standard Greene Climacteric Scale in Hong Kong. <i>Menopause</i> , 2010, 17, 630-635.	0.8	20
209	Testosterone for low libido in postmenopausal women not using systemic oestrogen therapy. <i>Medical Journal of Australia</i> , 2009, 191, 134-135.	0.8	2
210	Lack of Knowledge of Hormone Receptor Status and Use of Endocrine Therapy in Invasive Breast Cancer. <i>Journal of Women's Health</i> , 2009, 18, 1975-1980.	1.5	12
211	Are low levels of low back pain intensity and disability associated with reduced well-being in community-based women?. <i>Climacteric</i> , 2009, 12, 266-275.	1.1	12
212	Bone marrow lesions predict increase in knee cartilage defects and loss of cartilage volume in middle-aged women without knee pain over 2 years. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 850-855.	0.5	75
213	Testosterone for Low Libido. <i>New England Journal of Medicine</i> , 2009, 360, 728-729.	13.9	1
214	The Effect of Transdermal Testosterone on Mammographic Density in Postmenopausal Women Not Receiving Systemic Estrogen Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4907-4913.	1.8	36
215	The Natural History of Bone Marrow Lesions in Community-Based Middle-Aged Women Without Clinical Knee Osteoarthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2009, 39, 213-217.	1.6	12
216	The Incidence of Invasive Breast Cancer Among Women Prescribed Testosterone for Low Libido. <i>Journal of Sexual Medicine</i> , 2009, 6, 1850-1856.	0.3	38

#	ARTICLE	IF	CITATIONS
217	A Randomized Trial of Oral DHEA Treatment for Sexual Function, Well-Being, and Menopausal Symptoms in Postmenopausal Women with Low Libido. <i>Journal of Sexual Medicine</i> , 2009, 6, 2579-2590.	0.3	44
218	The Relationship Between Self-Reported Sexual Satisfaction and General Well-Being in Women. <i>Journal of Sexual Medicine</i> , 2009, 6, 2690-2697.	0.3	267
219	The relationship between knowledge of family history and cancer characteristics at diagnosis in women newly-diagnosed with invasive breast cancer. <i>Familial Cancer</i> , 2009, 8, 299-305.	0.9	9
220	Age-specific prevalence of, and factors associated with, different types of urinary incontinence in community-dwelling Australian women assessed with a validated questionnaire. <i>Maturitas</i> , 2009, 62, 134-139.	1.0	78
221	The safety of 52 weeks of oral DHEA therapy for postmenopausal women. <i>Maturitas</i> , 2009, 63, 240-245.	1.0	49
222	The Associations Between the Dominant and Nondominant Peak External Knee Adductor Moments During Gait in Healthy Subjects: Evidence for Symmetry. <i>Archives of Physical Medicine and Rehabilitation</i> , 2009, 90, 320-324.	0.5	25
223	Total cholesterol and triglycerides are associated with the development of new bone marrow lesions in asymptomatic middle-aged women - a prospective cohort study. <i>Arthritis Research and Therapy</i> , 2009, 11, R181.	1.6	87
224	Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal women with female sexual dysfunction. <i>Climacteric</i> , 2009, 12, 114-121.	1.1	10
225	Low back pain and disability in community-based women. <i>Menopause</i> , 2009, 16, 24-29.	0.8	17
226	Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen: A Phase III Research Study of Female Sexual Dysfunction in Women on Testosterone Patch Without Estrogen (APHRODITE). <i>Obstetrical and Gynecological Survey</i> , 2009, 64, 170-172.	0.2	0
227	Understanding female sexual function. <i>Menopause</i> , 2009, 16, 425-426.	0.8	9
228	In-vivo dosimetry from total body irradiation patients (2000-2006): results and analysis. <i>Australasian Physical and Engineering Sciences in Medicine</i> , 2008, 31, 191-195.	1.4	17
229	Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women. <i>Osteoporosis International</i> , 2008, 19, 1153-1160.	1.3	39
230	Static knee alignment is associated with the risk of unicompartmental knee cartilage defects. <i>Journal of Orthopaedic Research</i> , 2008, 26, 225-230.	1.2	53
231	Prevalence and incidence of urinary incontinence in women: Review of the literature and investigation of methodological issues. <i>International Journal of Urology</i> , 2008, 15, 230-234.	0.5	124
232	Use of a cancer registry is preferable to a direct-to-community approach for recruitment to a cohort study of wellbeing in women newly diagnosed with invasive breast cancer. <i>BMC Cancer</i> , 2008, 8, 126.	1.1	33
233	Negative beliefs about low back pain are associated with high pain intensity and high level disability in community-based women. <i>BMC Musculoskeletal Disorders</i> , 2008, 9, 148.	0.8	59
234	FSD PHARMACOTHERAPY: Tibolone and Transdermal E2/NETA for the Treatment of Female Sexual Dysfunction in Naturally Menopausal Women: Results of a Randomized Active-Controlled Trial. <i>Journal of Sexual Medicine</i> , 2008, 5, 646-656.	0.3	102

#	ARTICLE	IF	CITATIONS
235	Sexual Function in Well Women: Stratification by Sexual Satisfaction, Hormone Use, and Menopause Status. <i>Journal of Sexual Medicine</i> , 2008, 5, 1214-1222.	0.3	68
236	Assessing Sexual Function in Well Women: Validity and Reliability of the Monash Women's Health Program Female Sexual Satisfaction Questionnaire. <i>Journal of Sexual Medicine</i> , 2008, 5, 2575-2586.	0.3	19
237	Meniscal tear and increased tibial plateau bone area in healthy post-menopausal women. <i>Osteoarthritis and Cartilage</i> , 2008, 16, 268-271.	0.6	19
238	Vastus medialis cross-sectional area is associated with patella cartilage defects and bone volume in healthy women. <i>Osteoarthritis and Cartilage</i> , 2008, 16, 956-960.	0.6	8
239	Pharmacological Therapy for Female Sexual Dysfunction. <i>Drugs</i> , 2008, 68, 259-264.	4.9	15
240	Androgen Replacement Therapy in Androgen-Deficient Women with Hypopituitarism. <i>Drugs</i> , 2008, 68, 2085-2093.	4.9	6
241	Association between meniscal tears and the peak external knee adduction moment and foot rotation during level walking in postmenopausal women without knee osteoarthritis: a cross-sectional study. <i>Arthritis Research and Therapy</i> , 2008, 10, R58.	1.6	20
242	High sensitivity C-reactive protein is associated with lower tibial cartilage volume but not lower patella cartilage volume in healthy women at mid-life. <i>Arthritis Research and Therapy</i> , 2008, 10, R27.	1.6	21
243	What is the clinical and ethical importance of incidental abnormalities found by knee MRI?. <i>Arthritis Research and Therapy</i> , 2008, 10, R18.	1.6	14
244	Reprint of Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. <i>Maturitas</i> , 2008, 61, 17-26.	1.0	35
245	Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen. <i>New England Journal of Medicine</i> , 2008, 359, 2005-2017.	13.9	427
246	Methodology and Challenges to Recruitment to a Randomized, Double-Blind, Placebo-Controlled Trial of Oral DHEA in Postmenopausal Women. <i>Journal of Women's Health</i> , 2008, 17, 1559-1565.	1.5	8
247	The determinants of change in patella cartilage volume--a cohort study of healthy middle-aged women. <i>Rheumatology</i> , 2008, 47, 1426-1429.	0.9	32
248	Dehydroepiandrosterone Sulfate Levels Are Associated with More Favorable Cognitive Function in Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 801-808.	1.8	95
249	Safety and Efficacy of a Testosterone Metered-Dose Transdermal Spray for Treating Decreased Sexual Satisfaction in Premenopausal Women. <i>Annals of Internal Medicine</i> , 2008, 148, 569.	2.0	131
250	Sexual health consequences of premature ovarian failure. <i>Menopause</i> , 2008, 15, 5-6.	0.8	3
251	A pragmatic approach to the classification of menopausal status for community-based research. <i>Menopause</i> , 2008, 15, 978-983.	0.8	35
252	Effects of the route of estrogen administration on insulinlike growth factor-I, IGF binding protein-3, and insulin resistance in healthy postmenopausal women. <i>Menopause</i> , 2008, 15, 1065-1069.	0.8	8

#	ARTICLE	IF	CITATIONS
253	Effect of Testosterone Therapy versus Other Factors on the Self-reported Sexual Satisfaction of Premenopausal Women. <i>Annals of Internal Medicine</i> , 2008, 149, 361.	2.0	0
254	Treatment of vasomotor symptoms in the menopausal transition and postmenopausally: psychiatric comorbidity. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, S115-S137.	1.4	5
255	DHEA therapy for women: effect on sexual function and wellbeing. <i>Human Reproduction Update</i> , 2007, 13, 239-248.	5.2	86
256	The cross-sectional relationship between fortnightly exercise and knee cartilage properties in healthy adult women in midlife. <i>Menopause</i> , 2007, 14, 830-834.	0.8	32
257	Effects of tibolone and raloxifene on health-related quality of life and sexual function. <i>Maturitas</i> , 2007, 58, 164-173.	1.0	19
258	Endogenous androgen levels and cardiovascular risk profile in women across the adult life span. <i>Menopause</i> , 2007, 14, 630-638.	0.8	62
259	Factors affecting patella cartilage and bone in middle-aged women. <i>Arthritis and Rheumatism</i> , 2007, 57, 272-278.	6.7	33
260	Well-being, health-related quality of life and cardiovascular disease risk profile in women with subclinical thyroid disease ? a community-based study. <i>Clinical Endocrinology</i> , 2007, 66, 070210034307001-???	1.2	73
261	Androgen therapy in women: What we think we know. <i>Experimental Gerontology</i> , 2007, 42, 457-462.	1.2	16
262	Are the Endocrine Society's Clinical Practice Guidelines on Androgen Therapy in Women Misguided? A Commentary-Response. <i>Journal of Sexual Medicine</i> , 2007, 4, 1782-1783.	0.3	7
263	The Relationship between Endogenous Testosterone, Preandrogens, and Sex Hormone Binding Globulin and Knee Joint Structure in Women at Midlife. <i>Seminars in Arthritis and Rheumatism</i> , 2007, 37, 56-62.	1.6	29
264	A study of the prevalence and associations of subchondral bone marrow lesions in the knees of healthy, middle-aged women. <i>Osteoarthritis and Cartilage</i> , 2007, 15, 1437-1442.	0.6	81
265	Intervention: Androgens. , 2007, , 799-812.		0
266	Androgen Therapy in Women: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 3697-3710.	1.8	286
267	Polycystic Ovarian Syndrome: the Next Cardiovascular Dilemma in Women?. <i>Endocrinology and Metabolism Clinics of North America</i> , 2006, 35, 611-631.	1.2	8
268	Homocysteine, estrogen and cognitive decline. <i>Climacteric</i> , 2006, 9, 77-87.	1.1	10
269	Comparison of effects of pravastatin and hormone therapy on soluble P-selectin and platelet P-selectin expression in postmenopausal hypercholesterolemic women. <i>Maturitas</i> , 2006, 53, 158-165.	1.0	6
270	Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women. <i>Menopause</i> , 2006, 13, 770-779.	0.8	146

#	ARTICLE	IF	CITATIONS
271	Current Perspectives on the Use of Androgens in Women. <i>Seminars in Reproductive Medicine</i> , 2006, 24, 069-070.	0.5	0
272	Effects of intranasal 17 β -estradiol administration on serum bioactive interleukin-6 and C-reactive protein levels in healthy postmenopausal women. <i>Menopause</i> , 2006, 13, 840-845.	0.8	229
273	Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women. <i>Menopause</i> , 2006, 13, 387-396.	0.8	230
274	Testosterone aromatization and cognition in women: a randomized, placebo-controlled trial. <i>Menopause</i> , 2006, 13, 600-608.	0.8	41
275	Effects of aromatase inhibition on sexual function and well-being in postmenopausal women treated with testosterone: a randomized, placebo-controlled trial. <i>Menopause</i> , 2006, 13, 37-45.	0.8	76
276	Endogenous androgen levels and well-being: differences between premenopausal and postmenopausal women. <i>Menopause</i> , 2006, 13, 65-71.	0.8	53
277	REVIEW: Female Sexual Satisfaction and Pharmaceutical Intervention: A Critical Review of the Drug Intervention Studies in Female Sexual Dysfunction. <i>Journal of Sexual Medicine</i> , 2006, 3, 763-777.	0.3	34
278	Sagittal plane movement at the tibiofemoral joint influences patellofemoral joint structure in healthy adult women. <i>Osteoarthritis and Cartilage</i> , 2006, 14, 331-336.	0.6	13
279	Static knee alignment and its association with radiographic knee osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2006, 14, 958-962.	0.6	41
280	Factors affecting tibial plateau expansion in healthy women over 2.5 years: a longitudinal study. <i>Osteoarthritis and Cartilage</i> , 2006, 14, 1258-1264.	0.6	27
281	Foot rotation "A potential target to modify the knee adduction moment. <i>Journal of Science and Medicine in Sport</i> , 2006, 9, 67-71.	0.6	41
282	A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. <i>Psychoneuroendocrinology</i> , 2006, 31, 543-547.	1.3	106
283	Beyond human resource management in coöperatives. <i>Cross Cultural Management</i> , 2006, 13, 69-95.	1.2	16
284	The use of androgens for female sexual dysfunction. <i>Nature Reviews Urology</i> , 2006, 3, 176-177.	1.4	4
285	Factors affecting progression of knee cartilage defects in normal subjects over 2 years. <i>Rheumatology</i> , 2006, 45, 79-84.	0.9	116
286	Determinants of change in patella cartilage volume in healthy subjects. <i>Journal of Rheumatology</i> , 2006, 33, 1658-61.	1.0	8
287	The relationship between the knee adduction moment and knee pain in middle-aged women without radiographic osteoarthritis. <i>Journal of Rheumatology</i> , 2006, 33, 1845-8.	1.0	18
288	Determining the effects of androgen therapy on sexual well-being: a complex challenge. <i>Menopause</i> , 2005, 12, 359-360.	0.8	3

#	ARTICLE	IF	CITATIONS
289	Pharmacokinetics and Acute Safety of Inhaled Testosterone in Postmenopausal Women. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 177-184.	1.0	33
290	Adipose aromatase gene expression is greater in older women and is unaffected by postmenopausal estrogen therapy. <i>Menopause</i> , 2005, 12, 210-215.	0.8	66
291	The relationship between body composition and knee cartilage volume in healthy, middle-aged subjects. <i>Arthritis and Rheumatism</i> , 2005, 52, 461-467.	6.7	70
292	Association of cartilage defects with loss of knee cartilage in healthy, middle-age adults: A prospective study. <i>Arthritis and Rheumatism</i> , 2005, 52, 2033-2039.	6.7	237
293	Testosterone Patch Increases Sexual Activity and Desire in Surgically Menopausal Women with Hypoactive Sexual Desire Disorder. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5226-5233.	1.8	428
294	Tibial plateau size is related to grade of joint space narrowing and osteophytes in healthy women and in women with osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 1033-1037.	0.5	62
295	Androgen Levels in Adult Females: Changes with Age, Menopause, and Oophorectomy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 3847-3853.	1.8	841
296	Circulating Androgen Levels and Self-reported Sexual Function in Women. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 91.	3.8	451
297	Postmenopausal hormone therapy: from monkey glands to transdermal patches. <i>Journal of Endocrinology</i> , 2005, 185, 207-222.	1.2	33
298	Factors influencing longitudinal change in knee cartilage volume measured from magnetic resonance imaging in healthy men. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 1038-1042.	0.5	62
299	Treatment of menopausal symptoms: what shall we do now?. <i>Lancet, The</i> , 2005, 366, 409-421.	6.3	116
300	Measurement of total testosterone in women: comparison of a direct radioimmunoassay versus radioimmunoassay after organic solvent extraction and celite column partition chromatography. <i>Fertility and Sterility</i> , 2005, 84, 1698-1704.	0.5	26
301	Intranasal versus transdermal matrix oestrogen replacement in Australasian women. <i>Maturitas</i> , 2005, 51, 163-171.	1.0	9
302	Differential expression of factors involved in fat metabolism with age and the menopause transition. <i>Maturitas</i> , 2005, 51, 299-306.	1.0	62
303	Testosterone for peri and postmenopausal women. <i>The Cochrane Library</i> , 2005, , CD004509.	1.5	104
304	Self-reported Sexual Function in Women and Androgen Levels. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 2167.	3.8	0
305	Transdermal testosterone treatment in women. , 2005, , 67-73.		0
306	Dysmetabolic Syndrome in a Man with a Novel Mutation of the Aromatase Gene: Effects of Testosterone, Alendronate, and Estradiol Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 61-70.	1.8	315

#	ARTICLE	IF	CITATIONS
307	Tibial cartilage volume change in healthy postmenopausal women: a longitudinal study. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 444-449.	0.5	57
308	Testosterone Effects on the Breast: Implications for Testosterone Therapy for Women. <i>Endocrine Reviews</i> , 2004, 25, 374-388.	8.9	196
309	Association between knee cartilage volume and bone mineral density in older adults without osteoarthritis. <i>Rheumatology</i> , 2004, 43, 765-769.	0.9	22
310	Androgen insufficiency in women: diagnostic and therapeutic implications. <i>Human Reproduction Update</i> , 2004, 10, 421-432.	5.2	61
311	The use of testosterone after menopause. <i>The Journal of the British Menopause Society</i> , 2004, 10, 65-69.	1.3	5
312	Postmenopausal hormone therapy: the pros and cons. <i>Internal Medicine Journal</i> , 2004, 34, 109-114.	0.5	7
313	Summary of the Recommendations on Sexual Dysfunctions in Women. <i>Journal of Sexual Medicine</i> , 2004, 1, 24-34.	0.3	214
314	Endocrine Aspects of Female Sexual Dysfunction. <i>Journal of Sexual Medicine</i> , 2004, 1, 82-86.	0.3	98
315	Osteoarthritis and the postmenopausal woman: Epidemiological, magnetic resonance imaging, and radiological findings. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 34, 631-636.	1.6	49
316	Aminina Nud Mulumuluna (â€œYou Gotta Look After Yourselfâ€): Evaluation of the use of traditional art in health promotion for Aboriginal people in the Kimberley region of Western Australia. <i>Australian Psychologist</i> , 2004, 39, 107-113.	0.9	18
317	Relationship between the area of cartilage shown on the magnetic resonance imaging middleâ€slice image of the medial and lateral tibial cartilages with cartilage volume and grade of osteoarthritis over time. <i>Scandinavian Journal of Rheumatology</i> , 2004, 33, 87-93.	0.6	5
318	Postmenopausal testosterone therapy and breast cancer risk. <i>Maturitas</i> , 2004, 49, 267-275.	1.0	37
319	Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometriumâ€a pilot study. <i>Menopause</i> , 2004, 11, 167-175.	0.8	36
320	Profile of Female Sexual Function: a patient-based, international, psychometric instrument for the assessment of hypoactive sexual desire in oophorectomized women. <i>Menopause</i> , 2004, 11, 474-483.	0.8	85
321	Acute administration of conjugated equine oestrogen does not improve exercise-induced myocardial ischaemia in men with coronary artery disease. <i>Internal Medicine Journal</i> , 2003, 33, 221-224.	0.5	2
322	Hormone replacement therapy: current controversies. <i>Clinical Endocrinology</i> , 2003, 58, 249-261.	1.2	79
323	The role of androgen therapy. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2003, 17, 165-175.	2.2	18
324	Androgens in women. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2003, 85, 363-366.	1.2	136

#	ARTICLE	IF	CITATIONS
325	What is the Rationale for Androgen Therapy for Women?. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2003, 2, 77-84.	1.8	19
326	Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Menopause, 2003, 10, 390-398.	0.8	246
327	The effect of the knee adduction moment on tibial cartilage volume and bone size in healthy women. British Journal of Rheumatology, 2003, 43, 311-314.	2.5	67
328	New Markers for Cardiovascular Disease Risk in Women: Impact of Endogenous Estrogen Status and Exogenous Postmenopausal Hormone Therapy. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2470-2478.	1.8	112
329	Transition to raloxifene with and without low-dose estrogen therapy in postmenopausal women: effects on serum lipids and fibrinogen - a pilot study. Climacteric, 2003, 6, 347-353.	1.1	0
330	Climacteric symptoms among indigenous Australian women and a model for the use of culturally relevant art in health promotion. Menopause, 2003, 10, 345-351.	0.8	9
331	Menopause: new therapies. Medical Journal of Australia, 2003, 178, 634-637.	0.8	8
332	Letters to the Editor. Menopause, 2003, 10, 102-103.	0.8	2
333	Rationale for Treating Hypoandrogenism in Women. , 2003, , 365-379.		2
334	Effect of estrogen replacement therapy on patella cartilage in healthy women. Clinical and Experimental Rheumatology, 2003, 21, 79-82.	0.4	17
335	Transition to raloxifene with and without low-dose estrogen therapy in postmenopausal women: effects on serum lipids and fibrinogen - a pilot study. Climacteric, 2003, 6, 347-53.	1.1	0
336	Transition to raloxifene with and without low-dose estrogen therapy in postmenopausal women: effects on serum lipids and fibrinogen - a pilot study. Climacteric, 2003, 6, 347-353.	1.1	0
337	Risks of Postmenopausal Hormone ReplacementHormone Replacement Following Early Menopause. JAMA - Journal of the American Medical Association, 2002, 288, 2819.	3.8	10
338	Preliminary indication of a high prevalence of polycystic ovary syndrome in indigenous Australian women. Gynecological Endocrinology, 2002, 16, 443-446.	0.7	29
339	Postmenopausal Hormone-Replacement Therapy. New England Journal of Medicine, 2002, 346, 63-65.	13.9	22
340	Estrogen regulates development of the somatic cell phenotype in the eutherian ovary. FASEB Journal, 2002, 16, 1389-1397.	0.2	93
341	The effects of tibolone on mood and libido. Menopause, 2002, 9, 162-170.	0.8	81
342	Female androgen insufficiency: the princeton consensus statement on definition, classification, and assessment. Fertility and Sterility, 2002, 77, 660-665.	0.5	408

#	ARTICLE	IF	CITATIONS
343	When to suspect androgen deficiency other than at menopause1 1Reprints will not be available.. Fertility and Sterility, 2002, 77, 68-71.	0.5	66
344	Differing effects of low-dose estrogenâ€“progestin therapy and pravastatin in postmenopausal hypercholesterolemic women. Climacteric, 2002, 5, 341-350.	1.1	16
345	The role of androgen therapy. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2002, 16, 383-393.	1.4	9
346	Testosterone insufficiency in women: fact or fiction?. World Journal of Urology, 2002, 20, 106-110.	1.2	41
347	Phytoestrogens in the Context of SERMs. , 2002, , 345-363.		2
348	Preliminary indication of a high prevalence of polycystic ovary syndrome in indigenous Australian women. Gynecological Endocrinology, 2002, 16, 443-446.	0.7	1
349	Androgen Deficiency and Abnormality in Women. , 2002, , 477-488.		0
350	Estrogen and Androgen: Mood, Sexual Function, and Quality of Life in the Menopausal Woman. Medical Science Symposia Series, 2002, , 291-301.	0.0	0
351	Compartment differences in knee cartilage volume in healthy adults. Journal of Rheumatology, 2002, 29, 554-6.	1.0	38
352	Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women. Climacteric, 2002, 5, 341-50.	1.1	10
353	Testosterone influences libido and well being in women. Trends in Endocrinology and Metabolism, 2001, 12, 33-37.	3.1	157
354	The effects of Chinese medicinal herbs on postmenopausal vasomotor symptoms of Australian women. Medical Journal of Australia, 2001, 174, 68-71.	0.8	69
355	Phytoestrogen therapy for menopausal symptoms?. BMJ: British Medical Journal, 2001, 323, 354-355.	2.4	52
356	A double exposed portal image comparison between electronic portal imaging hard copies and port films in radiation therapy treatment setup confirmation to determine its clinical application in a radiotherapy center. International Journal of Radiation Oncology Biology Physics, 2001, 49, 191-198.	0.4	12
357	An External Perspective on the Report of the International Consensus Development Conference on Female Sexual Dysfunction: More Work to Be Done. Journal of Sex and Marital Therapy, 2001, 27, 131-133.	1.0	3
358	Dietary Soy Has Both Beneficial and Potentially Adverse Cardiovascular Effects: A Placebo-Controlled Study in Men and Postmenopausal Women1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3053-3060.	1.8	252
359	Users of oestrogen replacement therapy have more knee cartilage than non-users. Annals of the Rheumatic Diseases, 2001, 60, 332-336.	0.5	177
360	Minireview: Aromatase and the Regulation of Estrogen Biosynthesisâ€“Some New Perspectives. Endocrinology, 2001, 142, 4589-4594.	1.4	405

#	ARTICLE	IF	CITATIONS
361	Evidence That Parenteral Testosterone Therapy May Improve Endothelium-Dependent and -Independent Vasodilation in Postmenopausal Women Already Receiving Estrogen. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 158-161.	1.8	153
362	What Are "Normal" Testosterone Levels for Women?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1842-1846.	1.8	15
363	What Are "Normal" Testosterone Levels for Women?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1842-1843.	1.8	6
364	Dietary Soy Has Both Beneficial and Potentially Adverse Cardiovascular Effects: A Placebo-Controlled Study in Men and Postmenopausal Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3053-3060.	1.8	231
365	Phytoestrogens and breast cancer in postmenopausal women: a case control study. <i>Menopause</i> , 2000, 7, 289-296.	0.8	75
366	Effects of estradiol with and without testosterone on body composition and relationships with lipids in postmenopausal women. <i>Menopause</i> , 2000, 7, 395-401.	0.8	145
367	Androgens. , 2000, , 445-458.		1
368	Another role highlighted for estrogens in the male: Sexual behavior. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 14038-14040.	3.3	21
369	Testosterone and Sexual Desire in Women. <i>Journal of Sex Education and Therapy</i> , 2000, 25, 25-32.	0.3	28
370	The Role of Local Estrogen Biosynthesis in Males and Females. <i>Trends in Endocrinology and Metabolism</i> , 2000, 11, 184-188.	3.1	201
371	Phytoestrogens as Hormone Replacement Therapy for Postmenopausal Symptoms. <i>Growth Hormone</i> , 2000, , 83-107.	0.2	0
372	Identifying and promoting the specific nutrition and physical activity needs of women aged 40 and over. Summary. <i>Medical Journal of Australia</i> , 2000, 173, S109.	0.8	3
373	Androgen treatment in women. <i>Medical Journal of Australia</i> , 1999, 170, 545-549.	0.8	29
374	Androgen Replacement in Women: A Commentary. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 1886-1891.	1.8	111
375	Local estrogen biosynthesis in males and females.. <i>Endocrine-Related Cancer</i> , 1999, 6, 131-137.	1.6	147
376	Concurrent use of simvastatin and estrogen-progestin therapy compared with each therapy alone for hypercholesterolemia in postmenopausal women. <i>Climacteric</i> , 1999, 2, 181-188.	1.1	14
377	The therapeutic use of androgens in women. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1999, 69, 177-184.	1.2	56
378	Do intracrine mechanisms regulate aromatase expression?. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1999, 69, 447-452.	1.2	15

#	ARTICLE	IF	CITATIONS
379	Androgen Replacement in Women. , 1999, , 401-417.		1
380	Phytoestrogens in health and disease. Endocrine Reviews, 1999, 54, 185-210; discussion 210-1.	7.1	49
381	Should women be treated with testosterone?. Clinical Endocrinology, 1998, 49, 159-160.	1.2	4
382	The rationale for physiological testosterone replacement in women. Bailliere's Clinical Endocrinology and Metabolism, 1998, 12, 391-405.	1.0	22
383	Phytoestrogens in Clinical Practice. Integrative Medicine: Integrating Conventional and Alternative Medicine, 1998, 1, 27-34.	0.1	26
384	PREMATURE OVARIAN FAILURE. Endocrinology and Metabolism Clinics of North America, 1998, 27, 989-1006.	1.2	164
385	Phytoestrogens ¹ . Journal of Clinical Endocrinology and Metabolism, 1998, 83, 297-303.	1.8	273
386	Hormone-Replacement Therapy Compared with Simvastatin for Postmenopausal Women with Hypercholesterolemia. New England Journal of Medicine, 1998, 338, 63-64.	13.9	6
387	The clinical use of androgens in female sexual disorders. Journal of Sex and Marital Therapy, 1998, 24, 153-163.	1.0	41
388	Phytoestrogens. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 297-303.	1.8	294
389	Estrogen and Progestin Compared with Simvastatin for Hypercholesterolemia in Postmenopausal Women. New England Journal of Medicine, 1997, 337, 595-601.	13.9	189
390	Use of androgens in postmenopausal women. Current Opinion in Obstetrics and Gynecology, 1997, 9, 177-180.	0.9	16
391	Cardiovascular disease prevention in postmenopausal women: a clinician's perspective. Maturitas, 1997, 27, 1-3.	1.0	4
392	"Add-Back" Estrogen Reverses Cognitive Deficits Induced by a Gonadotropin-Releasing Hormone Agonist in Women with Leiomyomata Uteri--Author's Response. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 702-702.	1.8	0
393	Premature ovarian failure. Maturitas, 1996, 23, 1-8.	1.0	43
394	Clinical review 82: Androgens and the postmenopausal woman.. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2759-2763.	1.8	100
395	Clinical review 82: Androgens and the postmenopausal woman. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2759-2763.	1.8	74
396	Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas, 1995, 21, 227-236.	1.0	488

#	ARTICLE	IF	CITATIONS
397	Human chorionic gonadotrophin-induced suppression of serum inhibin involves reduction in ovarian inhibin α -subunit messenger RNA levels in the pregnant mare serum gonadotrophin-primed female rat. <i>Molecular and Cellular Endocrinology</i> , 1989, 61, 123-128.	1.6	6
398	The effect of hypophysectomy on inhibin production by adult rat ovaries: Changes in ovarian inhibin gene expression and serum inhibin. <i>Gynecological Endocrinology</i> , 1988, 2, 223-232.	0.7	7
399	Pregnant Mare's Serum Gonadotropin Stimulates Inhibin Subunit Gene Expression in the Immature Rat Ovary: Dose Response Characteristics and Relationships to Serum Gonadotropins, Inhibin, and Ovarian Steroid Content*. <i>Endocrinology</i> , 1988, 123, 2399-2407.	1.4	31
400	INHIBIN GENE EXPRESSION IN THE HUMAN CORPUS LUTEUM. <i>Journal of Endocrinology</i> , 1987, 115, R21-R23.	1.2	107
401	Inhibin α -subunit gene expression in the ovaries of immature female rats is stimulated by pregnant mare serum gonadotrophin. <i>Biochemical and Biophysical Research Communications</i> , 1986, 138, 1191-1195.	1.0	78
402	Testosterone use in women. , 0, , 494-516.		1
403	Androgen therapy for postmenopausal women. , 0, , 136-141.		0
404	Minireview: Aromatase and the Regulation of Estrogen Biosynthesisâ€”Some New Perspectives. , 0, .		121
405	Why Do the Clinical Sequelae of Estrogen Deficiency Affect Women More than Men?a. , 0, .		9
406	Androgen Replacement in Women: A Commentary. , 0, .		41
407	Phytoestrogens in the Context of SERMs. , 0, , 345-364.		0